Entera Bio Ltd.: Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal ...

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to submi ...
TMCnet

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with ...

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to ...
ABP News on MSNOpinion

Opinion | Golden dome and Sudarshan chakra: Survival kits in a new world order

The ongoing indigenous Ballistic Missile Defense (BMD) initiative, known as Sudarshan Chakra, has garnered significant ...
Interesting Engineering on MSN

China’s neighbor tests 2-layer ballistic missile defense shield for nuclear threats

India’s Defence Research and Development Organisation (DRDO) has completed three back-to-back flight tests of ...

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as ...
Kaleido Scope

BMD program launches Biotechnology minor

The University of Alabama at Birmingham’s Biomedical Sciences bachelor’s program is proud to launch its new Biotechnology minor. From cells to solutions, this minor equips its students with science ...

Plans for Brisbane 2032 Olympics athletes village at Hamilton reveal high-rises and tree-lined streets

The proposed design for the Brisbane 2032 Olympic village has been revealed. The Queensland government’s render, released on ...
FOX31 Denver

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is ...

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American ...
The Diplomat

Strategic Shifts: India’s MIRV Milestone and Nuclear Policy Dynamics

In this Jan. 23, 2013, file photo, an Agni-V Missile passes through the Rajpath during the full dress rehearsal for the Republic Day Parade 2013, in New Delhi, India. Credit: Indian Ministry of ...
Seeking Alpha

Exclusive BAC Article: Edgewise Therapeutics; DMD Data 1st Half Of 2024, Three Data Readouts BMD This Year, Late-Stage Program Advancements And Catalysts

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Edgewise Therapeutics (EWTX). The reason why I believe that it is important to go over this ...